Scientists modify CRISPR to epigenetically treat diabetes, kidney disease, muscular dystrophy

December 7, 2017, Salk Institute
The Belmonte lab's advanced in vivo Cas9-based epigenetic gene activation system enhances skeletal muscle mass (top) and fiber size growth (bottom) in a treated mouse (right) compared with an independent control (left). The fluorescent microscopy images at bottom show purple staining of the laminin glycoprotein in tibialis anterior muscle fibers. Credit: Salk Institute

Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.

Most CRISPR/Cas9 systems work by creating "double-strand breaks" (DSBs) in regions of the genome targeted for editing or for deletion, but many researchers are opposed to creating such breaks in the DNA of living humans. As a proof of concept, the Salk group used their new approach to treat several diseases, including diabetes, acute kidney disease, and muscular dystrophy, in mouse models.

"Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology," says Juan Carlos Izpisua Belmonte, a professor in Salk's Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. "We were able to get around that concern."

In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a "dead" form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted . But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.

Izpisua Belmonte's team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.

"The components all work together in the organism to influence endogenous genes," says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co-first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.

To test the method, the researchers used mouse models of , type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a of diabetes. For , the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.

"We were very excited when we saw the results in mice," adds Fumiyuki Hatanaka, a research associate in the lab and co-first author of the paper. "We can induce gene activation and at the same time see physiological changes."

Izpisua Belmonte's team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.

Explore further: Researchers devise improved gene-editing process for Duchenne muscular dystrophy

More information: Cell, Liao et al.: "In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-Epigenetic Modulation" www.cell.com/cell/fulltext/S0092-8674(17)31247-3 , DOI: 10.1016/j.cell.2017.10.025

Related Stories

Alternative CRISPR system is less specific, more robust

September 13, 2017

The genetic tool adept at line-by-line gene editing, CRISPR, has revolutionized the ability of scientists to manipulate genes for experimental, and perhaps someday therapeutic, purposes. But it comes in several varieties. ...

Recommended for you

Discovery could neutralize West Nile virus

November 20, 2018

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can "neutralize" the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) ...

The taming of the dog, cow, horse, pig and rabbit

November 20, 2018

Research at the Earlham Institute into one of the 'genetic orchestra conductors', microRNAs, sheds light on our selectively guided evolution of domestic pets and farmyard animals such as dogs and cows.

A Mexican cavefish with a scarred heart

November 20, 2018

Scientists are studying a guppy-sized, blind, translucent fish that lives in the cave systems of northern Mexico to figure out why some animals can regenerate their hearts, while others just scar. Their research appears November ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

baudrunner
4 / 5 (1) Dec 07, 2017
This brings to mind the Duke University Medical Center epigenetics study, in which a significant adaptation to a diet high in methyl contributors in pregnant agouti mice - that is, mice bred with a completely unmethylated agouti gene, producing obesity and high probability of debilitating disease, like diabetes, in maturity - led to the delivery of normal grey mouse babies with none of the physiological features of the mother, and who lived normal lifespans. http://www.nature...-12.html

Agouti gene may generate patterns from stripes to spots in vertebrates: https://phys.org/...ice.html

Migration of this knowledge to the current state of the art, as described in this article, seems natural.

SwamiOnTheMountain
1 / 5 (1) Dec 11, 2017
They could use this to activate genes, which they don't know what they do, and then see what they actually do.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.